XML 44 R32.htm IDEA: XBRL DOCUMENT
v3.23.1

Liabilities for puttable financial instrument | 12 Months Ended
--- | ---
Dec. 31, 2022
Liabilities for puttable financial instrument [Abstract] |
Liabilities for puttable financial instrument |
27 | Liabilities for puttable financial instrument
See accounting policies in note 36(J). On December 30, 2022, the Group acquired 74.39% of the issued share capital of ACT Genomics. In connection with the ACT Acquisition, a puttable financial instrument had been granted under the shareholders’ agreements to the remaining shareholders of ACT (the “NCI of ACT”), which the Group has an obligation to buy the remaining shares from the NCI of ACT at specified price if the NCI of ACT exercises the option before the contract’s expiry date. The puttable financial instrument is presented as a current financial liability in the consolidated financial statements due to a potential event could trigger within twelve months from the end of the reporting period. The movement of the liabilities for puttable financial instrument during year ended December 31, 2022 are analyzed as follows:
|  | 2022 |
|  | $ |
At January 1 |  |  | — |
Issuance of puttable financial instrument |  |  | 17,138,905 |
At December 31 |  |  | 17,138,905 |

X
- Definition Liabilities for puttable financial instrument. + References No definition available. + Details
Name: | pre_LiabilitiesForPuttableFinancialInstrument
Namespace Prefix: | pre_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liabilities for puttable financial instrument. + References No definition available. + Details
Name: | pre_LiabilitiesForPuttableFinancialInstrumentAbstract
Namespace Prefix: | pre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration